NCT03077269

Brief Summary

The purpose of this study is to understand what happens to platelets and blood clotting factors in burn patients over time. This study will also examine the role of microparticles (MPs), nanoparticles (NPs), and micro RNA in burns. The investigators will be looking at small particles of cells that are released into the blood. These particles have been found to be important in a variety of different diseases. The investigators believe that MPs, NPs, and micro RNA may play a role in development of inflammation, and infections in burn patients. Thus, hopefully, this study will help understand how to minimize transfusions and bleeding in burn patients as well as how to reduce inflammation and infections in burn patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

March 1, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 10, 2017

Completed
8.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 19, 2025

Completed
Last Updated

February 13, 2026

Status Verified

January 1, 2026

Enrollment Period

9.1 years

First QC Date

March 1, 2017

Last Update Submit

February 10, 2026

Conditions

Keywords

burncoagulationinflammation

Outcome Measures

Primary Outcomes (2)

  • measurement of coagulation factor levels over time

    coagulation factor levels will be measured using laboratory testing

    during hospital admission for up to 30 days

  • development of sepsis and infections

    sepsis and infection will be monitored using CRP values by lab testing as well as blood and urine cultures

    during hospital admission for up to 30 days

Eligibility Criteria

Age18 Years - 110 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patients presenting with 2nd or 3rd degree burns older than age 18

You may qualify if:

  • Adults \>18 years of age with 2nd and/or 3rd degree burns and any degree of associated trauma
  • Elderly

You may not qualify if:

  • Children \<18 years of age
  • Prisoners
  • Pregnant females

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rochester

Rochester, New York, 14642, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma and microparticles

MeSH Terms

Conditions

BurnsThrombosisInflammation

Condition Hierarchy (Ancestors)

Wounds and InjuriesEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 1, 2017

First Posted

March 10, 2017

Study Start

May 1, 2016

Primary Completion

May 19, 2025

Study Completion

May 19, 2025

Last Updated

February 13, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations